Agilent allies with Agendia on molecular cancer diagnostics

Agilent Technologies has expanded its longstanding commercial relationship with Agendia to develop a new molecular cancer diagnostic tool.

The companies will work together to create an RNA sequencing kit version of Agendia's MammaPrint and BluePrint tests, which are used to determine the risk of metastasis in breast cancer patients and identify the molecular subtype of the cancer.

With the new RNA-Seq kit, Agendia will be able to develop and perform these tests as next-generation sequencing (NGS) assays, allowing them to be run in decentralised settings that can utilise a wider range of instruments.

This will also make it possible to perform these tests at locations closer to patients, further expanding access to diagnosis and treatment. The initial phase of kit development is expected to be completed in 2017, providing early access to limited markets in Europe.

Jacob Thaysen, president of Agilent's diagnostics and genomics group, said: "This agreement leverages Agendia's expertise in molecular cancer diagnostics and Agilent's leading NGS target enrichment technologies to ultimately enable the best treatment decision to be made for each individual."

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.